Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia.
acute myeloid leukaemia
haploidentical donor
matched unrelated donor
peripheral blood stem cell transplantation
post‐transplant cyclophosphamide
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
22 Oct 2024
22 Oct 2024
Historique:
received:
25
06
2024
accepted:
30
09
2024
medline:
23
10
2024
pubmed:
23
10
2024
entrez:
23
10
2024
Statut:
aheadofprint
Résumé
HLA-haploidentical haematopoietic cell transplantation with post-transplant cyclophosphamide (PTCy-haplo) is emerging as an effective alternative due to donor availability and safety. We conducted a nationwide retrospective study comparing the outcomes of PTCy-haplo with both anti-thymocyte globulin (ATG)-free and ATG-administered matched unrelated donors (MUD) transplantation, using peripheral blood stem cells as the first transplantation for acute myeloid leukaemia (AML). Our study showed a lower and slower haematopoietic recovery and a higher incidence of infection-related deaths after PTCy-haplo than after MUD transplantation. In addition, we revealed an increased risk of acute and chronic graft-versus-host disease (GVHD) in ATG-free MUD transplantation in comparison to PTCy-haplo. For grades III-IV acute GVHD, the hazard ratio (HR) was 2.71 (95% CI, 1.46-5.01), and for extensive chronic GVHD, the HR was 3.11 (95% CI, 2.07-4.68). There was no significant difference regarding overall survival amongst the groups. In addition, GVHD-free relapse-free survival (GRFS) was lower in ATG-free MUD transplantation than in PTCy-haplo (HR, 1.46; 95% CI, 1.17-1.82). Notably, ATG-administered MUD transplantation showed no significant difference in GRFS from PTCy-haplo, negating the advantage of PTCy. Our results suggest that PTCy-haplo could be viable for AML patients without an HLA-matched related donor.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
Références
D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2020;26(8):e177–e182.
Gagelmann N, Bacigalupo A, Rambaldi A, Hoelzer D, Halter J, Sanz J, et al. Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: a systematic review and meta‐analysis. JAMA Oncol. 2019;5(12):1739–1748.
Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system. Int J Hematol. 2007;86(3):269–274.
Atsuta Y. Introduction of transplant registry unified management program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA‐related data). Int J Hematol. 2016;103(1):3–10.
Kanda J. Scripts for TRUMP data analyses. Part II (HLA‐related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol. 2016;103(1):11–19.
Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft‐versus‐host disease‐free, relapse‐free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125(8):1333–1338.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828.
Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft‐versus‐host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28(3):250–259.
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628–1633.
Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced‐intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367–369.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649–655.
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)‐specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–2919.
Yanada M, Mori J, Aoki J, Harada K, Mizuno S, Uchida N, et al. Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients. Leuk Lymphoma. 2018;59(3):601–609.
Kanda Y. Investigation of the freely available easy‐to‐use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
Rashidi A, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Cashen AF, et al. Comparison of outcomes after peripheral blood haploidentical versus matched unrelated donor allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia: a retrospective single‐center review. Biol Blood Marrow Transplant. 2016;22(9):1696–1701.
Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033–1040.
How J, Slade M, Vu K, DiPersio JF, Westervelt P, Uy GL, et al. T cell‐replete peripheral blood haploidentical hematopoietic cell transplantation with post‐transplantation cyclophosphamide results in outcomes similar to transplantation from traditionally matched donors in active disease acute myeloid leukemia. Biol Blood Marrow Transplant. 2017;23(4):648–653.
Devillier R, Legrand F, Rey J, Castagna L, Fürst S, Granata A, et al. HLA‐matched sibling versus unrelated versus haploidentical related donor allogeneic hematopoietic stem cell transplantation for patients aged over 60 years with acute myeloid leukemia: a single‐center donor comparison. Biol Blood Marrow Transplant. 2018;24(7):1449–1454.
Brissot E, Labopin M, Ehninger G, Stelljes M, Brecht A, Ganser A, et al. Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the acute leukemia working party of the EBMT. Haematologica. 2019;104(3):524–532.
Rieger MJ, Stolz SM, Müller AM, Schwotzer R, Nair G, Schneidawind D, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm. Bone Marrow Transplant. 2023;58(10):1121–1129.
Atsuta Y, Sugita J, Nakamae H, Maruyama Y, Ishiyama K, Shiratori S, et al. Comparable survival outcomes with haploidentical stem cell transplantation and unrelated bone marrow transplantation. Bone Marrow Transplant. 2022;57(12):1781–1787.
Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Post‐transplantation cyclophosphamide prevents graft‐versus‐host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest. 2019;129(6):2357–2373.
Bolaños‐Meade J, Hamadani M, Wu J, al Malki MM, Martens MJ, Runaas L, et al. Post‐transplantation cyclophosphamide‐based graft‐versus‐host disease prophylaxis. N Engl J Med. 2023;388(25):2338–2348.
Penack O, Abouqateb M, Peczynski C, Boreland W, Kröger N, Stelljes M, et al. ATG or post‐transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation? Leukemia. 2024;38(5):1156–1163.
Jimenez Jimenez A, Komanduri K, Brown S, Wang T, Pereira D, Goodman M, et al. Improved GRFS after posttransplant cyclophosphamide‐based vs ATG‐based HLA‐mismatched unrelated donor transplant. Blood Adv. 2022;6(15):4491–4500.
Mehta RS, Saliba RM, Rondon G, al‐Atrash G, Bashir Q, Hosing CM, et al. Post‐transplantation cyclophosphamide versus tacrolimus and methotrexate graft‐versus‐host disease prophylaxis for HLA‐matched donor transplantation. Transplant Cell Ther. 2022;28(10):695.e1–695.e10.
Mikulska M, Bartalucci C, Raiola AM, Oltolini C. Does PTCY increase the risk of infections? Blood Rev. 2023;62:101092.
Wang Y, Liu QF, Lin R, Yang T, Xu YJ, Mo XD, et al. Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long‐term follow‐up of a multicenter, randomized controlled trial. Sci Bull (Beijing). 2021;66(24):2498–2505.
Fuji S, Sugita J, Najima Y, Konishi T, Tanaka T, Ohigashi H, et al. Low‐ versus standard‐dose post‐transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation. Br J Haematol. 2024;204(3):959–966.